Equity Investment Corp trimmed its position in CVS Health (NYSE:CVS) by 14.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 900,862 shares of the pharmacy operator’s stock after selling 157,713 shares during the quarter. CVS Health comprises approximately 2.2% of Equity Investment Corp’s holdings, making the stock its 26th largest position. Equity Investment Corp owned 0.09% of CVS Health worth $65,312,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Bontempo Ohly Capital Mgmt LLC raised its stake in CVS Health by 0.5% during the 2nd quarter. Bontempo Ohly Capital Mgmt LLC now owns 21,830 shares of the pharmacy operator’s stock valued at $1,756,000 after purchasing an additional 109 shares during the last quarter. ELCO Management Co. LLC raised its stake in CVS Health by 1.4% during the 2nd quarter. ELCO Management Co. LLC now owns 15,900 shares of the pharmacy operator’s stock valued at $1,279,000 after purchasing an additional 215 shares during the last quarter. Auxier Asset Management raised its stake in CVS Health by 0.6% during the 2nd quarter. Auxier Asset Management now owns 67,449 shares of the pharmacy operator’s stock valued at $5,427,000 after purchasing an additional 400 shares during the last quarter. Sii Investments Inc. WI raised its stake in CVS Health by 2.2% during the 2nd quarter. Sii Investments Inc. WI now owns 20,381 shares of the pharmacy operator’s stock valued at $1,630,000 after purchasing an additional 443 shares during the last quarter. Finally, Psagot Investment House Ltd. raised its stake in CVS Health by 0.9% during the 2nd quarter. Psagot Investment House Ltd. now owns 52,421 shares of the pharmacy operator’s stock valued at $4,218,000 after purchasing an additional 447 shares during the last quarter. Institutional investors and hedge funds own 83.97% of the company’s stock.
In other news, EVP Helena Foulkes sold 19,965 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.61% of the stock is currently owned by corporate insiders.
CVS opened at $66.61 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.52 and a current ratio of 1.02. CVS Health has a twelve month low of $60.14 and a twelve month high of $84.00. The stock has a market capitalization of $67,060.56, a PE ratio of 11.29, a PEG ratio of 1.10 and a beta of 1.05.
CVS Health (NYSE:CVS) last posted its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. During the same quarter in the prior year, the firm earned $1.71 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. analysts expect that CVS Health will post 6.3 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 3.00%. The ex-dividend date is Friday, April 20th. CVS Health’s payout ratio is 33.90%.
Several equities analysts recently commented on CVS shares. Robert W. Baird cut their target price on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, February 9th. ValuEngine cut shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Vetr cut shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price for the company. in a research note on Thursday, January 4th. UBS upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, January 4th. Finally, Needham & Company LLC upgraded shares of CVS Health from a “buy” rating to a “strong-buy” rating and upped their target price for the company from $88.00 to $100.00 in a research note on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $86.65.
ILLEGAL ACTIVITY WARNING: “Equity Investment Corp Has $65.31 Million Stake in CVS Health (CVS)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2018/04/19/equity-investment-corp-has-65-31-million-stake-in-cvs-health-cvs.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.